Evidence map›Paper›PMID 33486801›Full record

ArticleJournal of applied toxicology : JAT2021

Summary of reference chemicals evaluated by the fish short-term reproduction assay, OECD TG229, using Japanese Medaka, Oryzias latipes.

Yuta Onishi, Norihisa Tatarazako, Masaaki Koshio, Tetsuro Okamura, Haruna Watanabe, Atsushi Sawai, Jun Yamamoto, Hidenori Ishikawa, Tomomi Sato, Yukio Kawashima and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of applied toxicology : JAT, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Yuta OnishiInstitute of Environmental Ecology, IDEA Consultants, Inc., Yaizu, Japan.
Norihisa TatarazakoDepartment of Science and Technology for Biological Resources and Environment, Graduate School of Agriculture, Ehime University, Matsuyama, Japan.ORCID 0000-0001-7098-8809
Masaaki KoshioCenter for Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan.
Tetsuro OkamuraInstitute of Environmental Ecology, IDEA Consultants, Inc., Yaizu, Japan.
Haruna WatanabeCenter for Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan.
Atsushi SawaiInstitute of Environmental Ecology, IDEA Consultants, Inc., Yaizu, Japan.
Jun YamamotoInstitute of Environmental Ecology, IDEA Consultants, Inc., Yaizu, Japan.
Hidenori IshikawaInstitute of Environmental Ecology, IDEA Consultants, Inc., Yaizu, Japan.
Tomomi SatoNanobioscience, Yokohama City University, Yokohama, Japan.
Yukio KawashimaJapan NUS Co., Tokyo, Japan.
Kunihiko YamazakiEnvironmental Health Department, Ministry of the Environment, Tokyo, Japan.
Taisen IguchiNanobioscience, Yokohama City University, Yokohama, Japan.
Institute for Development and Economic Analysis · IDNational Institute for Environmental Studies · JPYokohama City University · JPEngineering Advancement Association of Japan · JPMinistry of the Environment · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Under the Organisation for Economic Co-operation and Development (OECD), the Ministry of the Environment of Japan (MOE) added Japanese medaka (Oryzias latipes) to the test guideline fish short-term reproduction assay (FSTRA) developed by the United States Environmental Protection Agency (US EPA) using fathead minnow (Pimephales promelas). The FSTRA was designed to detect endocrine disrupting effects of chemicals interacting with the hypothalamic-pituitary-gonadal axis (HPG axis) such as agonists or antagonists on the estrogen receptor (Esr) and/or the androgen receptor (AR) and steroidogenesis inhibitors. We conducted the FSTRA with Japanese medaka, in accordance with OECD test guideline number 229 (TG229), for 16 chemicals including four Esr agonists, two Esr antagonists, three AR agonists, two AR antagonists, two steroidogenesis inhibitors, two progesterone receptor agonists, and a negative substance, and evaluated the usability and the validity of the FSTRA (TG229) protocol. In addition, in vitro reporter gene assays (RGAs) using Esr1 and ARβ of Japanese medaka were performed for the 16 chemicals, to support the interpretation of the in vivo effects observed in the FSTRA. In the present study, all the test chemicals, except an antiandrogenic chemical and a weak Esr agonist, significantly reduced the reproductive status of the test fish, that is, fecundity or fertility, at concentrations where no overt toxicity was observed. Moreover, vitellogenin (VTG) induction in males and formation of secondary sex characteristics (SSC), papillary processes on the anal fin, in females was sensitive endpoints to Esr and AR agonistic effects, respectively, and might be indicators of the effect concentrations in long-term exposure. Overall, it is suggested that the in vivo FSTRA supported by in vitro RGA data can adequately detect effects on the test fish, O. latipes, and probably identify the mode of action (MOA) of the chemicals tested.

Indexed as

Androgen Receptor AntagonistsAndrogensAnimalsBiological AssayEndocrine DisruptorsEstrogen Receptor AntagonistsEstrogensFemaleMaleOryziasReceptors, ProgesteroneReproductionToxicity TestsAndrogen Receptor AntagonistsAndrogensEndocrine DisruptorsEstrogen Receptor AntagonistsEstrogensReceptors, Progesteroneendocrine disrupting effectJapanese medakaOECD TG229Oryzias latipesreproduction

Identifiers

PMID33486801
PMCPMC8359193
OpenAlexW3125621122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.